Table 2.
Transplant outcomes in the intervention and control groups
| Intervention (n = 51) | Control (n = 54) | p value | |
|---|---|---|---|
| Drug levels | |||
| TAC trough level, ng/mL | 5.3 ± 1.2 | 5.0 ± 1.2 | 0.282 |
| TAC CVa | 23.9 ± 13.5 | 25.1 ± 11.4 | 0.645 |
| MPA trough level, μg/mL | 2.8 ± 1.6 | 2.6 ± 1.3 | 0.600 |
| MPA CVa | 37.9 ± 17.3 | 38.9 ± 19.4 | 0.783 |
| eGFR | |||
| 4 weeks | 67.8 ± 18.2 | 71.4 ± 21.8 | 0.365 |
| 8 weeks | 67.9 ± 19.7 | 71.3 ± 19.2 | 0.373 |
| 12 weeks | 66.7 ± 19.4 | 71.3 ± 21.6 | 0.262 |
| 16 weeks | 67.6 ± 17.4 | 72.4 ± 21.9 | 0.213 |
| 20 weeks | 66.3 ± 18.0 | 71.6 ± 21.8 | 0.182 |
| 24 weeks | 65.2 ± 18.9 | 70.2 ± 21.0 | 0.203 |
| Number of events, n (%) | |||
| De novo anti-HLA antibodies | 3 (5.9) | 8 (14.8) | 0.135 |
| BK viremia | 1 (2.0) | 1 (1.9) | 1.000 |
| BPAR | – | – | |
| DCGL | – | – | |
Values are shown as mean ± standard deviation or number (%)
BPAR Biopsy-proven acute rejection, CV Coefficient of variation, DCGL Death-censored graft loss, eGFR estimated glomerular filtration rate, HLA Human leukocyte antigen, MPA Mycophenolic acid, TAC Tacrolimus
aCV = (standard deviation/mean) × 100%